Justin Ted Gerstle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Justin Ted Gerstle has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Ahmad Oudeh
Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
2 shared publications - Anita P. Price
Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
2 shared publications - Gaetano Rocco
Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
2 shared publications - Gerald Behr
Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
2 shared publications - Hayun H. Kim
Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
2 shared publications - Jacqueline S. Cho
Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
2 shared publications
Latest Publications
- Open Access
Three-Dimensional Imaging, Printing, and Augmented Reality in Surgical Oncology: A Descriptive Implementation Framework at a Comprehensive Cancer Center
Background: Three-dimensional (3D) visualization of radiological imaging has emerged as a valuable tool in surgical oncology, with applications spanning diagnostics, perioperative planning, intraoperative guidance, and patient communication. Despite its growing clinical relevance, integration into routine surgical workflows remains inconsistent and poorly standardized across specialties. Methods: We describe select cases illustrating a multispecialty feasibility and implementation experience evaluating the integration of 3D reconstruction, 3D printing, and augmented reality into surgical oncology workflows across a comprehensive cancer center. Describing cases and series of interest, we demonstrate how a structured implementation workflow was applied covering image acquisition, segmentation, volumetric rendering, and modality selection based on the specific clinical problem. A feasibility framework is proposed in terms of workflow integration, modality-to-problem fit, and clinical utility as described by the operating team. Results: Seven select case groups spanning pediatric, head and neck, urologic, gynecologic, and thoracic surgical oncology were included, with group sizes ranging from 1 to 14 patients. In 3 patients with hepatoblastoma, 3D printed anatomical models were successfully integrated into patient and family education consultations to convey tumor extent and the scope of planned resection. Segmentation-based visualization was implemented for preoperative planning in 2 patients with skull base malignancies, with the 3D workflow described as useful for operative planning by the operating team in both cases. Augmented reality (AR)-assisted 3D reconstruction was incorporated into the planning workflow for 3 patients undergoing robotic partial nephrectomy for complex renal tumors, facilitating review of vascular anatomy and assessment of the feasibility of nephron-sparing surgery. In 2 patients with suspected advanced ovarian cancer, volumetric rendering with AR was integrated into preoperative resectability planning. Among 14 patients undergoing chest wall tumor resection, patient-specific 3D printed ribcage replicas were used for preoperative implant preparation. In a separate cohort of 2 chest wall patients, AR visualization was used for spatial surgical planning. Conclusions: Across diverse oncologic contexts and surgical specialties, 3D reconstruction, printing, and augmented reality were successfully integrated into existing perioperative workflows, with each modality selected based on the specific clinical problem at hand. This experience describes a structured, modality-matched implementation framework that may serve as a practical starting point for institutions seeking to incorporate these technologies. Prospective, controlled studies are needed to establish independent clinical benefit. Broader adoption will require standardized selection criteria, prospective evaluation, and workflow adaptation for centers beyond high-volume academic institutions.
Open AccessThree-Dimensional Imaging, Printing, and Augmented Reality in Surgical Oncology: A Descriptive Implementation Framework at a Comprehensive Cancer Center
Background: Three-dimensional (3D) visualization of radiological imaging has emerged as a valuable tool in surgical oncology, with applications spanning diagnostics, perioperative planning, intraoperative guidance, and patient communication. Despite its growing clinical relevance, integration into routine surgical workflows remains inconsistent and poorly standardized across specialties. Methods: We describe select cases illustrating a multispecialty feasibility and implementation experience evaluating the integration of 3D reconstruction, 3D printing, and augmented reality into surgical oncology workflows across a comprehensive cancer center. Describing cases and series of interest, we demonstrate how a structured implementation workflow was applied covering image acquisition, segmentation, volumetric rendering, and modality selection based on the specific clinical problem. A feasibility framework is proposed in terms of workflow integration, modality-to-problem fit, and clinical utility as described by the operating team. Results: Seven select case groups spanning pediatric, head and neck, urologic, gynecologic, and thoracic surgical oncology were included, with group sizes ranging from 1 to 14 patients. In 3 patients with hepatoblastoma, 3D printed anatomical models were successfully integrated into patient and family education consultations to convey tumor extent and the scope of planned resection. Segmentation-based visualization was implemented for preoperative planning in 2 patients with skull base malignancies, with the 3D workflow described as useful for operative planning by the operating team in both cases. Augmented reality (AR)-assisted 3D reconstruction was incorporated into the planning workflow for 3 patients undergoing robotic partial nephrectomy for complex renal tumors, facilitating review of vascular anatomy and assessment of the feasibility of nephron-sparing surgery. In 2 patients with suspected advanced ovarian cancer, volumetric rendering with AR was integrated into preoperative resectability planning. Among 14 patients undergoing chest wall tumor resection, patient-specific 3D printed ribcage replicas were used for preoperative implant preparation. In a separate cohort of 2 chest wall patients, AR visualization was used for spatial surgical planning. Conclusions: Across diverse oncologic contexts and surgical specialties, 3D reconstruction, printing, and augmented reality were successfully integrated into existing perioperative workflows, with each modality selected based on the specific clinical problem at hand. This experience describes a structured, modality-matched implementation framework that may serve as a practical starting point for institutions seeking to incorporate these technologies. Prospective, controlled studies are needed to establish independent clinical benefit. Broader adoption will require standardized selection criteria, prospective evaluation, and workflow adaptation for centers beyond high-volume academic institutions.
- 29 September 2026
- Published by Wolters Kluwer Health in Liver Transplantation
Definitive surgical outcomes in children with advanced hepatoblastoma (PRETEXT III–IV): A retrospective single-center Canadian experience
Children with advanced hepatoblastoma (PRETEXT III–IV) often require complex surgical decision-making; however, contemporary data describing long-term outcomes and recurrence patterns across the full spectrum of definitive surgery remain limited. We included 68 patients with PRETEXT III and IV who underwent definitive liver resection (LR, n=41) or liver transplantation (LT, n=27). The primary objective of this study was to characterize survival and recurrence patterns after surgical clearance of primary liver disease. The median age at diagnosis was 18 months (IQR, 9–36). All the patients received neoadjuvant chemotherapy. With a median follow-up of 62 months (IQR, 25–146), 5-year overall survival was 79% (95% CI: 65%–97%) after LT and 88% (95% CI 78%–100%) after LR. After LT, recurrence occurred in 6 of the 27 (22%) patients, including isolated lung metastases (n=4), combined lung–graft involvement (n=1), and isolated graft relapse (n=1). Recurrence occurred in 6 of the 41 patients (15%) after LR, involving the liver (n=2), lung (n=2), combined liver and pulmonary disease progression (n=1), and unspecified site (n=1). Among LR patients with residual pulmonary nodules at surgery (n=8), progression occurred in 3, 2 of whom died. The majority of events occurred within the first postoperative year after LR or LT. All deaths (n=10, 15%) were attributable to tumor recurrence or progression of known lung metastasis, including all post-LT recurrences. There were no perioperative or graft-related deaths. Univariate analysis showed that a serum alpha-fetoprotein decline of <95% and distant metastasis at diagnosis were associated with poor prognosis after LT and LR. Mortality in this cohort was entirely disease-related, occurring after recurrence or progression of residual metastases rather than from surgical modality. Incorporating AFP trend, pulmonary response, and detailed imaging into preoperative assessment may help identify high-risk patients and support more informed surgical decision-making.
- 29 September 2026
- Published by Wolters Kluwer Health in Liver Transplantation
Definitive surgical outcomes in children with advanced hepatoblastoma (PRETEXT III–IV): A retrospective single-center Canadian experience
Children with advanced hepatoblastoma (PRETEXT III–IV) often require complex surgical decision-making; however, contemporary data describing long-term outcomes and recurrence patterns across the full spectrum of definitive surgery remain limited. We included 68 patients with PRETEXT III and IV who underwent definitive liver resection (LR, n=41) or liver transplantation (LT, n=27). The primary objective of this study was to characterize survival and recurrence patterns after surgical clearance of primary liver disease. The median age at diagnosis was 18 months (IQR, 9–36). All the patients received neoadjuvant chemotherapy. With a median follow-up of 62 months (IQR, 25–146), 5-year overall survival was 79% (95% CI: 65%–97%) after LT and 88% (95% CI 78%–100%) after LR. After LT, recurrence occurred in 6 of the 27 (22%) patients, including isolated lung metastases (n=4), combined lung–graft involvement (n=1), and isolated graft relapse (n=1). Recurrence occurred in 6 of the 41 patients (15%) after LR, involving the liver (n=2), lung (n=2), combined liver and pulmonary disease progression (n=1), and unspecified site (n=1). Among LR patients with residual pulmonary nodules at surgery (n=8), progression occurred in 3, 2 of whom died. The majority of events occurred within the first postoperative year after LR or LT. All deaths (n=10, 15%) were attributable to tumor recurrence or progression of known lung metastasis, including all post-LT recurrences. There were no perioperative or graft-related deaths. Univariate analysis showed that a serum alpha-fetoprotein decline of <95% and distant metastasis at diagnosis were associated with poor prognosis after LT and LR. Mortality in this cohort was entirely disease-related, occurring after recurrence or progression of residual metastases rather than from surgical modality. Incorporating AFP trend, pulmonary response, and detailed imaging into preoperative assessment may help identify high-risk patients and support more informed surgical decision-making.
- Open Access
- 17 September 2026
- Published by MDPI AG in Preprints.org
Three-Dimensional Imaging, Printing, and Mixed Reality in Surgical Oncology: A Feasibility and Implementation Framework at a Comprehensive Cancer Center
Background: Three-dimensional (3D) visualization of radiological imaging has emerged as a valuable tool in surgical oncology, with applications spanning diagnostics, perioperative planning, intraoperative guidance, and patient communication. Despite the growing clinical relevance of these technologies, integration into routine surgical workflows remains inconsistent and poorly standardized across specialties. Methods: We describe a multispecialty feasibility and implementation experience evaluating the integration of 3D reconstruction, 3D printing, and augmented reality into surgical oncology workflows at a comprehensive cancer center. For each case group, a structured implementation workflow was applied covering image acquisition, segmentation, volumetric rendering, and modality selection based on the specific clinical problem. Feasibility was assessed in terms of workflow integration, modality-to-problem fit, and clinical utility as described by the operating team. Results: We identified seven case groups spanning pediatric, head and neck, urologic, gynecologic, and thoracic surgical oncology (range, 1–16 patients/group). In hepatoblastoma cases, 3D-printed anatomical models were successfully integrated into patient and family education consultations to convey tumor extent and the scope of planned resection. Segmentation-based visualization was implemented for preoperative planning in two patients with skull-based malignancies; the surgical team described the 3D workflow as useful for operative planning. Augmented reality (AR)-assisted 3D reconstruction was incorporated into the planning workflow for three patients undergoing robotic partial nephrectomy for complex renal tumors, facilitating review of the vascular anatomy and assessment of whether nephron-sparing surgery was feasible. In two patients with suspected advanced ovarian cancer, volumetric rendering with AR was integrated into preoperative resectability planning. Among 14 patients undergoing resection of chest wall tumor, patient-specific 3D-printed rib cage replicas were used for preoperative implant preparation. In two other patients with chest wall tumors, AR visualization was used for spatial surgical planning. Conclusion: Across diverse oncologic contexts and surgical specialties, 3D reconstruction, printing, and AR were successfully integrated into existing perioperative workflows, with each modality selected based on the specific clinical problem at hand. This experience demonstrates the feasibility of a structured, modality-matched implementation framework that can serve as a practical starting point for institutions seeking to incorporate these technologies into surgical oncology practice. Broader adoption will require standardized selection criteria, prospective evaluation, and workflow adaptation for centers beyond high-volume academic institutions.
- 17 September 2026
- Published by MDPI AG in Preprints.org
Open AccessThree-Dimensional Imaging, Printing, and Mixed Reality in Surgical Oncology: A Feasibility and Implementation Framework at a Comprehensive Cancer Center
Background: Three-dimensional (3D) visualization of radiological imaging has emerged as a valuable tool in surgical oncology, with applications spanning diagnostics, perioperative planning, intraoperative guidance, and patient communication. Despite the growing clinical relevance of these technologies, integration into routine surgical workflows remains inconsistent and poorly standardized across specialties. Methods: We describe a multispecialty feasibility and implementation experience evaluating the integration of 3D reconstruction, 3D printing, and augmented reality into surgical oncology workflows at a comprehensive cancer center. For each case group, a structured implementation workflow was applied covering image acquisition, segmentation, volumetric rendering, and modality selection based on the specific clinical problem. Feasibility was assessed in terms of workflow integration, modality-to-problem fit, and clinical utility as described by the operating team. Results: We identified seven case groups spanning pediatric, head and neck, urologic, gynecologic, and thoracic surgical oncology (range, 1–16 patients/group). In hepatoblastoma cases, 3D-printed anatomical models were successfully integrated into patient and family education consultations to convey tumor extent and the scope of planned resection. Segmentation-based visualization was implemented for preoperative planning in two patients with skull-based malignancies; the surgical team described the 3D workflow as useful for operative planning. Augmented reality (AR)-assisted 3D reconstruction was incorporated into the planning workflow for three patients undergoing robotic partial nephrectomy for complex renal tumors, facilitating review of the vascular anatomy and assessment of whether nephron-sparing surgery was feasible. In two patients with suspected advanced ovarian cancer, volumetric rendering with AR was integrated into preoperative resectability planning. Among 14 patients undergoing resection of chest wall tumor, patient-specific 3D-printed rib cage replicas were used for preoperative implant preparation. In two other patients with chest wall tumors, AR visualization was used for spatial surgical planning. Conclusion: Across diverse oncologic contexts and surgical specialties, 3D reconstruction, printing, and AR were successfully integrated into existing perioperative workflows, with each modality selected based on the specific clinical problem at hand. This experience demonstrates the feasibility of a structured, modality-matched implementation framework that can serve as a practical starting point for institutions seeking to incorporate these technologies into surgical oncology practice. Broader adoption will require standardized selection criteria, prospective evaluation, and workflow adaptation for centers beyond high-volume academic institutions.
- Open Access
- 18 February 2026
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 20
International Society of Paediatric Surgical Oncology (IPSO) Minimally Invasive Surgery (MIS) Guidelines
Paediatric oncology surgeons play a crucial role in diagnosing, staging, and treating malignant solid tumors. In recent years, many solid tumour protocols have advocated for a more tailored surgical approach to both the primary tumour site and metastatic disease. The integration of Minimally Invasive Surgery (MIS) into paediatric oncology practice has gained popularity over the past few decades. While the benefits of MIS are well established in non-oncologic surgery, its role in paediatric solid tumours is still evolving and, in many cases, lacks high-quality evidence. These IPSO-MIS guidelines guidelines aim to provide practical surgical recommendations for diverse clinical scenarios, addressing the needs of both High-Income Countries (HICs) and Low- and Middle-Income Countries (LMICs). The contributing authors represent both settings, ensuring a comprehensive and inclusive perspective. We hope that these guidelines will contribute to improving outcomes for children with cancer worldwide.
- 18 February 2026
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 20
Open AccessInternational Society of Paediatric Surgical Oncology (IPSO) Minimally Invasive Surgery (MIS) Guidelines
Paediatric oncology surgeons play a crucial role in diagnosing, staging, and treating malignant solid tumors. In recent years, many solid tumour protocols have advocated for a more tailored surgical approach to both the primary tumour site and metastatic disease. The integration of Minimally Invasive Surgery (MIS) into paediatric oncology practice has gained popularity over the past few decades. While the benefits of MIS are well established in non-oncologic surgery, its role in paediatric solid tumours is still evolving and, in many cases, lacks high-quality evidence. These IPSO-MIS guidelines guidelines aim to provide practical surgical recommendations for diverse clinical scenarios, addressing the needs of both High-Income Countries (HICs) and Low- and Middle-Income Countries (LMICs). The contributing authors represent both settings, ensuring a comprehensive and inclusive perspective. We hope that these guidelines will contribute to improving outcomes for children with cancer worldwide.